Standpoint Research Upgrades Teva Pharma (TEVA) to Buy
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.77 +1.74%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 21 | New: 11
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 21 | New: 11
Join SI Premium – FREE
Standpoint Research upgraded Teva Pharma (NYSE: TEVA) from Hold to Buy with a price target of $65.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $49.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Upgrades Best Buy (BBY) to Buy, 'AI may turn “trade” into investment'
- Leerink Upgrades Innate Pharma S.A. (IPHA) to Outperform
- Citi upgrades Everpure to Buy, raises price target to $118
Create E-mail Alert Related Categories
UpgradesRelated Entities
Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
